New article in mood disorders
Publication of a new article written by ETAP-Lab evaluating the effects of green algae on anxiety and depression : “Evaluation of the antidepressant- and anxiolytic-like effects of a hydrophilic extract from the green seaweed Ulva sp. in rats”, Nutr Neurosci. 2017 Jan 19:1-9. PMID:28102110
Save the date: STROK@LLIANCE kick-off meeting and website on May 10th
Launch of STROK@LLIANCE, the new preclinical platform resulting from the alliance of the academic Experimental Stroke Research Platform (ESRP) and the well-established CRO ETAP-Lab. For half a day, neurologists, neuroradiologists, neurosurgeons, researchers, specialists in preclinical and clinical trials, will give you an overview of stroke etiology, current acute management practices and animal modeling. Next, they will discuss with you during a debate: "The transition from preclinical drug to clinical drug for stroke: What are the essential information for clinicians about pharmacology issues?"
ETAP-Lab participation to NutrEvent 2017
ETAP-Lab will participate on June 14 & 15 to NutrEvent in Lille. Contact us for scheduling a meeting there with Pascale ROZAN or Jean-François BISSON. Join us to our stand For more information about this meeting click here.
ETAP-Lab participation to ESOC 2017
Dr Nicolas VIOLLE is the executive partner of STROK@LLIANCE, the new preclinical platform resulting from the alliance of the public Experimental Stroke Research Platform (ESRP; Université de Caen Normandie) and the well-established French private CRO, ETAP-Lab. He will participate to ESOC 2017 in order to meet players in the pharmaceutical industry and to promote STROK@LLIANCE the only CRO 100% dedicated to Preclinical Stroke Research. Contact :contact@strokalliance.com
ETAP-Lab participation to AFSTAL 2017
This year conferences of AFSTAL will focus on Ethology in Animal Experimentation, that is one of the main concerns of our company.
New model in dermatology
In order to strenghten its leading position on preclinical expertise in the field of Dermatology, ETAP-Lab finalizes the development of a model of atopic dermatitis in BALB/c mice using the chemical agent DNCB. This model will shortly be added to ETAP-Lab’s catalog in order to test new active compounds against this pathology. For more information please contact us.
Join ETAP-Lab at Hi Europe & Ni
Join us at Hi Europe & Ni Hi Europe &Ni promises you a complete 360 degree perspective of the nutrition and health ingredients industry through an exclusive offering of new ingredients & solutions, innovative tours, presentations & live demonstrations. We are in Frankfurt from 29 November – 1 December and would like to invite you to our booth! WE’LL BE WAITING FOR YOU AT STAND F48-5 We will showcase our latest innovations and our team will be ready to meet you face-to-face.. We look forward to
Poster presentation at the 4th World Congress on Targeting Microbiota
DERMATOLOGY : ETAP-Lab's preclinical results obtained for PiLeJe will be presented in a poster “Identification of two probiotic strains able to prevent skin inflammation in a murine model” at the 4th World Congress on Targeting Microbiota, October 17-19, 2016, Institut Pasteur, Paris (France). Congress Website PiLeJe Website
ETAP-Lab associates with MIRCen to perform a MRI translationnal study in stroke
ETAP-Lab is pleased to announce a 12-month collaboration with the MIRCen imaging platform directed by Pr. Philippe Hantraye(French Atomic Energy Commission (CEA), Fontenay-aux-Roses, France). This collaboration is happening within the context of a specific project aimed at supporting the translation of an innovative drug for acute ischemic stroke from preclinic to clinic. ETAP-Lab is contributing its original thrombo-embolic stroke model in rats, while MIRCen brings its outstanding expertise in the field of MRI in rodents. Stroke is one of the most prevalent life-threatening conditions in